As reimbursements decline, will care that dermatologists provide suffer?
With the presidential election behind us and myriad changes about to hit healthcare, dermatologists need to anticipate cuts in reimbursement by not only government, but also private, insurers. And if dermatologists are to combat the impact these declining reimbursements may have on their practices, they need to start implementing more aggressive patient education and retention efforts now.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.